Authors: Jorga, KM Davis, TL Kurth, MC Saint-Hilaire, MH LeWitt, PA Fotteler, B Zurcher, G Rabbia, M

Citation: Km. Jorga et al., Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism, CLIN NEUROP, 23(2), 2000, pp. 98-105

Authors: Jorga, KM Fotteler, B Gasser, R Banken, L Birnboeck, H

Citation: Km. Jorga et al., Lack of interaction between tolcapone and tolbutamide in healthy volunteers, J CLIN PHAR, 40(5), 2000, pp. 544-551

Authors: Jorga, KM Fotteler, B Modi, M Rabbia, M

Citation: Km. Jorga et al., Effect of tolcapone on the haemodynamic effects and tolerability of desipramine, EUR NEUROL, 44(2), 2000, pp. 94-103

Authors: Buller, R Jorga, KM

Citation: R. Buller et Km. Jorga, Monoamine oxidase inhibitors (including the newer reversible compounds), MIL DRUG TH, 2000, pp. 41-53

Authors: Jorga, KM Larsen, JP Beiske, A Schleimer, M Fotteler, B Schmitt, M Moe, B

Citation: Km. Jorga et al., The effect of tolcapone on the pharmacokinetics of beserazide, EUR J NEUR, 6(2), 1999, pp. 211-219

Authors: Jorga, KM Nicholl, DJ

Citation: Km. Jorga et Dj. Nicholl, COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/carbidopa (Sinemet (R)), BR J CL PH, 48(3), 1999, pp. 449-452